The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| COLL | +0.33% | +93.42% | +14.1% | +187% |
| S&P | +18.37% | +110.18% | +16.02% | +229% |
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
It's not every day that a company graduates to a slot in a high-profile stock index.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $188.00M | 29.4% |
| Gross Profit | $108.38M | 19.4% |
| Gross Margin | 57.65% | -4.9% |
| Market Cap | $950.44M | -9.8% |
| Market Cap / Employee | $2.66M | 0.0% |
| Employees | 357 | 81.2% |
| Net Income | $11.98M | -38.9% |
| EBITDA | $92.29M | 11.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $137.20M | -20.6% |
| Accounts Receivable | $213.02M | 15.9% |
| Inventory | 38.1 | 36.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $885.82M | 136.2% |
| Short Term Debt | $65.92M | -64.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 2.74% | -6.1% |
| Return On Invested Capital | 6.73% | 5.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $72.37M | 7.8% |
| Operating Free Cash Flow | $72.44M | 7.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 16.67 | 15.51 | 24.60 | 28.55 | 128.69% |
| Price to Book | 5.77 | 3.94 | 4.10 | 4.05 | -14.50% |
| Price to Sales | 2.59 | 1.82 | 1.48 | 1.63 | -27.53% |
| Price to Tangible Book Value | -4.63 | -1.08 | -1.14 | -1.26 | -64.15% |
| Price to Free Cash Flow TTM | 8.06 | 5.65 | 4.99 | 5.73 | 21.36% |
| Enterprise Value to EBITDA | 24.88 | 20.19 | 21.56 | 20.21 | 5.54% |
| Free Cash Flow Yield | 12.4% | 17.7% | 20.1% | 17.5% | -17.60% |
| Return on Equity | 42.9% | 32.6% | 19.2% | 16.2% | -66.23% |
| Total Debt | $993.21M | $979.91M | $965.74M | $951.74M | 70.12% |
COLL earnings call for the period ending September 30, 2021.
COLL earnings call for the period ending June 30, 2021.
COLL earnings call for the period ending March 31, 2021.
COLL earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
